LEADER 02585nam 2200481 450 001 9910819854403321 005 20210401162058.0 010 $a90-04-42022-3 024 7 $a10.1163/9789004420229 035 $a(CKB)4920000000127068 035 $z(OCoLC)1127667415 035 $a(nllekb)BRILL9789004420229 035 $a(MiAaPQ)EBC6126536 035 $a(EXLCZ)994920000000127068 100 $a20200423d2020 uy 0 101 0 $aeng 135 $aurun####uuuua 181 $ctxt$2rdacontent 182 $cn$2rdamedia 183 $anc$2rdacarrier 200 14$aThe Catholic Church and the Dutch Bible $efrom the Council of Trent to the Jansenist controversy (1564-1733) /$fby Els Agten 210 1$aLeiden ;$aBoston :$cBrill,$d[2020] 210 4$dİ2020 215 $a1 online resource 225 1 $aBrill's Series in Church History ;$vVolume 80 300 $aRevision of the author's thesis (doctoral)--Catholic University of Leuven, 2014, under the title: "Meint gy dat gy ook wel verstaet, het gene gy leest?" : the Catholic Church and the Dutch Bible : from the Council of Trent to the Jansenist Controversy (1564-1733). 311 $a90-04-42001-0 320 $aIncludes bibliographical references and index. 330 $a"In The Catholic Church and the Bible: From the Council of Trent to the Jansenist Controversy (1564-1733), Els Agten studies the impact of Jansenism and anti-Jansenism on the ideas regarding vernacular Bible reading and Bible production in the Low Countries in the broader seventeenth century. The book provides a review of sixteenth- and seventeenth-century book censorship and an analysis of the ideas and the writings of ten protagonists, including theologians, Bible translators, ecclesiastical authorities and representatives of Port-Royal. This way, Agten demonstrates that the Jansenists were stimulating the laity, with the inclusion of women and children, to read the Bible in the vernacular, with no restrictions whatsoever. Their opponents, in contrast, adopted a more wary position". 410 0$aBrill's series in church history ;$vVolume 80. 606 $aJansenists$zNetherlands$xHistory 607 $aNetherlands$xChurch history$y16th century 607 $aNetherlands$xChurch history$y17th century 615 0$aJansenists$xHistory. 676 $a220.53931 700 $aAgten$b Els$f1985-$4aut$01281809 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910819854403321 996 $aThe Catholic Church and the Dutch Bible$94023877 997 $aUNINA LEADER 03913nam 2200733Ia 450 001 9910957468703321 005 20251116230952.0 010 $a9786610844333 010 $a9780309133999 010 $a0309133998 010 $a9781280844331 010 $a1280844337 010 $a9780309667111 010 $a0309667119 035 $a(CKB)1000000000522507 035 $a(EBL)3378200 035 $a(SSID)ssj0000277648 035 $a(PQKBManifestationID)11213015 035 $a(PQKBTitleCode)TC0000277648 035 $a(PQKBWorkID)10234779 035 $a(PQKB)10631704 035 $a(MiAaPQ)EBC3378200 035 $a(Au-PeEL)EBL3378200 035 $a(CaPaEBR)ebr10170927 035 $a(CaONFJC)MIL84433 035 $a(OCoLC)923276655 035 $a(Perlego)4735347 035 $a(BIP)14085711 035 $a(EXLCZ)991000000000522507 100 $a20070123d2007 uy 0 101 0 $aeng 135 $aurcn||||||||| 181 $ctxt 182 $cc 183 $acr 200 00$aCancer biomarkers $ethe promises and challenges of improving detection and treatment /$fCommittee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment, Institute of Medicine of the National Academies ; Sharyl J. Nass and Harold L. Moses, editors 205 $a1st ed. 210 $aWashington, D.C. $cNational Academies Press$dc2007 215 $a1 online resource (252 p.) 300 $aDescription based upon print version of record. 311 08$a9780309103862 311 08$a030910386X 320 $aIncludes bibliographical references. 327 $a""Front Matter""; ""Reviewers""; ""Acknowledgments""; ""Contents""; ""Boxes, Figure, and Tables""; ""Summary""; ""1 Introduction""; ""2 Methods, Tools, and Resources Needed to Discover and Develop Biomarkers""; ""3 Guidelines, Standards, Oversight, and Incentives Needed for Biomarker Development""; ""4 Methods and Process Needed for Clinical Adoption and Evaluation of Biomarker-Based Diagnostics""; ""Acronyms and Glossary"" 327 $a""Appendix: Developing Biomarker-Based Tools for Cancer Screening, Diagnosis,and Treatment: The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary--Margie Patlak and Sharyl Nass, Rapporteurs"" 330 $aMany cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority of patients undergoing therapy. Thus, there is tremendous opportunity to improve the outcome for people with cancer by enhancing detection and treatment approaches. Biomarkers will be instrumental in making that transition. Advances in biotechnology and genomics have given scientists new hope that biomarkers can be used to improve cancer screening and detection, to improve the drug development process, and to enhance the effectiveness and safety of cancer care by allowing physicians to tailor treatment for individual patients-an approach known as personalized medicine. However, progress overall has been slow, despite considerable effort and investment, and there are still many challenges and obstacles to overcome before this paradigm shift in oncology can become a reality. 606 $aTumor markers 606 $aCancer$xDiagnosis 606 $aCancer$xTreatment 615 0$aTumor markers. 615 0$aCancer$xDiagnosis. 615 0$aCancer$xTreatment. 676 $a616.99/4075 701 $aNass$b Sharyl J$0857626 701 $aMoses$b Harold L$01809537 712 02$aNational Academies Press (U.S.) 712 02$aInstitute of Medicine (U.S.).$bCommittee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment. 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910957468703321 996 $aCancer biomarkers$94364048 997 $aUNINA